In a sign of growing support for its immunotherapeutic approach to treat cancer, Dutch biotech ISA Pharmaceuticals B.V. has received a €26m money injection from new and existing investors, including US partner Regeneron Pharmaceuticals, Inc.. which used the round to lift its equity stake further in the private Netherlands-based company.
Proceeds of the round, announced 13 July, will be used to advance ISA’s lead product ISA101b towards its first marketing...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)